Immune System News and Research

RSS

BPA shows tangible effects on health endpoints at high dosage levels

Endocrine-disrupting chemicals (EDCs)-such as BPA-can show tangible effects on health endpoints at high dosage levels, yet those effects do not predict how EDCs will affect the endocrine system at low doses, according to a recent study accepted for publication in The Endocrine Society's Endocrine Reviews.

30 Mar 2012

Needle-free vaccine shows promise against RSV in children

Researchers at the University of Saskatchewan are closing in on a needle-free vaccine for respiratory syncytial virus (RSV), a major cause of respiratory illness in children under two years of age.

30 Mar 2012

Infection with dengue virus turns on feeding-related genes in mosquitoes

Researchers at the Johns Hopkins Bloomberg School of Public Health have, for the first time, shown that infection with dengue virus turns on mosquito genes that makes them hungrier and better feeders, and therefore possibly more likely to spread the disease to humans.

30 Mar 2012

Treatment areas of ambulances fared well when tested for dangerous bacteria

Treatment areas of ambulances fared well when tested for dangerous bacteria, according to a new study published in the April issue of the American Journal of Infection Control, the official publication of APIC - the Association for Professionals in Infection Control and Epidemiology.

30 Mar 2012

Women with HIV superinfection have more potent antibody responses

Women who have been infected by two different strains of HIV from two different sexual partners - a condition known as HIV superinfection - have more potent antibody responses that block the replication of the virus compared to women who've only been infected once. These findings, by researchers at Fred Hutchinson Cancer Research Center in Seattle, are published online March 29 in PLoS Pathogens.

30 Mar 2012

OMRF researchers identify three lupus genes

Three newly confirmed lupus genes are opening new avenues of research at the Oklahoma Medical Research Foundation.

30 Mar 2012

Researchers generate artificial thymus tissue to enable T cell maturation

The thymus plays a key role in the body's immune response. It is here where the T lymphocytes or T cells, a major type of immune defence cells, mature. Different types of T cells, designated to perform specific tasks, arise from progenitor cells that migrate to the thymus from the bone marrow. Researchers at the Max Planck Institute of Immunology and Epigenetics in Freiburg have generated artificial thymus tissue in a mouse embryo to enable the maturation of immune cells.

30 Mar 2012

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.

29 Mar 2012

ProImmune introduces Special Assay Service

ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.

29 Mar 2012

Anthropologists discover lower testosterone levels in Tsimane men

As part of an isolated indigenous group in central Bolivia, Tsimane men spend much of their time hunting, foraging, fishing, and clearing land by hand to grow crops. Their ability to maintain the physical activity required to survive each day might imply they have higher than average male testosterone levels.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

MiR-375 regulates IL-13-induced changes in allergic diseases

Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).

29 Mar 2012

Potential new therapy that kills cancer cells selectively

Researchers have made a drug that helps the immune system to break down cancerous tumors. It has worked on breast, bowel, prostate, ovarian, brain, bladder and liver cancers, while previous studies show it can also be used to fight some blood cancers. If given early, the drug could even be a cure, researchers say.

28 Mar 2012

UM completes most extensive full vascularized composite allograft to date

The University of Maryland released details today of the most extensive full face transplant completed to date, including both jaws, teeth, and tongue.

28 Mar 2012

Possible link between sleep apnea and post-surgical delirium

An anecdotal observation of a possible link between sleep apnea and post-surgical delirium has been measured and confirmed by a team of researchers at the Duke University Medical Center.

28 Mar 2012

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or “bad” cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.

27 Mar 2012

Improvement in collaboration between TB and HIV services saves 910 000 lives

An estimated 910 000 lives were saved globally over six years by improving collaboration between TB and HIV services that protect people living with HIV from TB, according to global health impact figures released today.

27 Mar 2012

Gold nanoparticles used to introduce chemical residues into the immune system

Developing a drug or vaccine requires a delicate balancing act with the immune system. On one hand, medications need to escape detection by the immune system in order to perform their function. But vaccinations - de-activated versions of a disease or virus - need to do the reverse. They prompt the immune system to create protective antibodies.

27 Mar 2012

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers.

27 Mar 2012